☆ 4.5 Article

Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort

ARTHRITIS & RHEUMATOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort

Amit Saxena et al.

Summary: Most SLE patients with confirmed COVID-19 were able to produce and maintain a serological response despite the use of a variety of immunosuppressants, providing reassurance about the efficacy and durability of humoral immunity and possible protection against re-infection with SARS-CoV-2.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Letter Rheumatology

SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease

Kristin M. D'Silva et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

S. F. Lumley et al.

Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity

Rahul Subramanian et al.

Summary: The study suggests that asymptomatic infections play a significant role in the spread and resurgence of COVID-19, even though it is challenging to accurately estimate their contributions due to changes in testing capacity. Even if asymptomatic infections have lower transmission rates, they still comprise a substantial portion of the force of infection along with presymptomatic cases.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon et al.

Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Ulf M. Geisen et al.

Summary: In this study, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in immunosuppressed patients were compared with healthy controls. The results showed that all study participants developed antibodies, with lower IgG titres in patients compared to controls. Side effects were minimal and no disease flares were observed, demonstrating the efficiency and safety of mRNA vaccines in this cohort despite its small size.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Review Rheumatology

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

Filippo Fagni et al.

Summary: Patients with immune-mediated inflammatory diseases do not have an increased risk of SARS-CoV-2 infection or severe COVID-19, and certain medications like cytokine inhibitors may even lower the risk of severe illness. However, glucocorticoids might worsen COVID-19 outcomes, and the immune response to vaccination in these patients could be somewhat reduced.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study

Parakkal Deepak et al.

Summary: Patients with CID show immune response to mRNA-based SARS-CoV-2 vaccines, but some may have lower antibody levels, especially those receiving glucocorticoids and B-cell depletion therapy. Further studies are needed to confirm these preliminary findings.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Rheumatology

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Jeffrey A. Sparks et al.

Summary: This study investigated the baseline use of biologic or targeted synthetic disease-modifying antirheumatic drugs and COVID-19 outcomes in patients with rheumatoid arthritis. The results showed that patients treated with rituximab or Janus kinase inhibitors were associated with worse COVID-19 severity, emphasizing the need for prioritizing risk mitigation strategies for these individuals.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Rebecca H. Haberman et al.

Summary: The study found that patients with immune-mediated inflammatory diseases (IMIDs) on methotrexate treatment showed impaired humoral and cellular immune response to COVID-19 mRNA vaccines, while healthy subjects and IMID patients on biologic treatments demonstrated strong antibody responses. These results suggest that different strategies may need to be explored to enhance immunization efficacy for IMID patients on methotrexate treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Immunology

Early Virus Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-19) With a History of Coinfection With Human Immunodeficiency Virus Type 1 and Hepatitis C Virus

Juanjuan Zhao et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Editorial Material Medicine, Research & Experimental

SARS-CoV-2: a storm is raging

Savannah F. Pedersen et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Letter Medicine, General & Internal

Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York

Rebecca Haberman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Rheumatology

COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes

Rebecca H. Haberman et al.

ARTHRITIS & RHEUMATOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

David Simon et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Seasonal coronavirus protective immunity is short-lasting

Arthur W. D. Edridge et al.

NATURE MEDICINE (2020)

Add to Collection

Article Health Care Sciences & Services

Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification

Wansu Chen et al.

BMC MEDICAL RESEARCH METHODOLOGY (2018)

Add to Collection

© Peeref 2019-2024. All rights reserved.